West Pharmaceutical Services, Inc.: How Are They Dealing With The Intensifying Competition In Biologics? 

West Pharmaceuticals experienced a challenging second quarter in 2024, with lower-than-expected performance due to ongoing customer destocking activities. Despite these conditions, the company remains confident in a recovery, expecting improvements in the latter half of the year with a focus on their Proprietary Products segment, particularly within biologics. This optimism for recovery is further supported by enhanced capabilities and expansions in manufacturing aimed at meeting the surging demand in biologics, high-value products (HVP), and regulatory-facing solutions.